YUTIQ™ (flucloxacillin acetate intravitreal implant) 0.18 mg for intravitreal injection

Initial U.S. Approval: 1963

INDICATIONS AND USAGE

- For ophthalmic intravitreal injection. (2.1)
- The intravitreal injection procedure should be carried out under aseptic conditions. (2.2)
- Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for new or worsened inflammation. (2.4)

DOSAGE FORMS AND STRENGTHS

- Non-biodegradable intravitreal implant containing 0.18 mg flucloxacillin acetate in a drug delivery system. (3)

ADVERSE REACTIONS

- Intravitreal injections have been associated with endophthalmitis, eye infection, inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the injection. (5.1)
- Use of corticosteroids may produce posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. (5.2)
- The implant may migrate into the anterior chamber if the posterior lens capsule is not intact. (5.3)

CONTRAINDICATIONS

- Ocular or periorcular infections (4.1)
- Hypersensitivity (4.2)

WARNINGS AND PRECAUTIONS

- Intravitreal injections have been associated with endophthalmitis, eye infection, inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the injection. (5.1)
- Use of corticosteroids may produce posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. (5.2)
- The implant may migrate into the anterior chamber if the posterior lens capsule is not intact. (5.3)

ADVERSE REACTIONS

In controlled studies, the most common adverse reaction reported were cataract development and increases in intraocular pressure. (2.3)

To report SUSPECTED ADVERSE REACTIONS, contact EyePoint Pharmaceuticals US, Inc. at 1-888-812-6198 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION

Revision: 10/2018

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 General Dosing Information

2.2 Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

4.1 Ocular or Periorcular infections

4.2 Hypersensitivity

5 WARNINGS AND PRECAUTIONS

5.1 Intravitreal Injection-related Events

5.2 Stored-related Effects

5.3 Risk of Inclination Migration

6 ADVERSE REACTIONS

6.1 Clinical Studies Experience

11.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

11.2 Mechanism of Action

11.3 Pharmacodynamics

11.4 Pharmacokinetics

12 USE IN SPECIFIC POPULATIONS

12.1 Geriatric Use

12.2 Pregnancy

12.3 Lactation

12.4 Pediatric Use

12.5 Nursing Mothers

13 NONCLINICAL TOXICOLOGY

13.1 Animal Toxicology

14 CLINICAL STUDIES

14.1 Open-label Studies

14.2 Randomized, masked trials

14.3 Adjunctive Treatment

14.4 Comparative trials

14.5 Double-masked, randomized controlled trials

15 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.
FM 452.58, molecular formula C_{23}H_{27}O_{3}, fluocinolone acetonide is a white or almost white, microcrystalline powder, practically insoluble in water, soluble in methanol, ethanol, chloroform and acetone, and sparingly soluble in ether.

Fluocinolone acetonide is a white or almost white, microcrystalline powder, practically insoluble in water, or in the Ames test (S. typhimurium and E. coli) and the in vitro assay (N=214 Patients).

Table 2: Summary of Elevated IOP Related Adverse Reactions

<table>
<thead>
<tr>
<th>Time to First Recurrence of Uveitis (ITT; all randomized subjects)</th>
<th>Study 1</th>
<th>Study 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eyes with recurrence within 6 months, n (%)</td>
<td>16 (33%)</td>
<td>33 (66%)</td>
</tr>
<tr>
<td>Difference (95% CI) in recurrence rates</td>
<td>40% (49%, 73%)</td>
<td>32% (15%, 48%)</td>
</tr>
<tr>
<td>P-value</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

Table 3: Efficacy Results of Recurrence of Uveitis in Randomized Study Eyes

Average IOP values for each treatment group are shown in Figure 1: Mean IOP During the Studies.

14. CLINICAL STUDIES

The efficacy of YUTIQ was assessed in two randomized (2:1, YUTIQ: sham-injection), multi-centre, double-blind, parallel-group studies (NCT #01694186 and #02746991) that enrolled patients with non-infectious uveitis affecting the posterior segment of the eye. The primary efficacy endpoint in both trials was the proportion of patients who experienced a recurrence of uveitis in the study eye within the 18-month follow-up period. Recurrence of uveitis was defined as either deterioration in visual acuity, vitreous haze attributable to non-infectious uveitis or the need for rescue medications.

Figure 2: Time to First Recurrence of Uveitis (ITT; All Randomized Patients)

Time to First Recurrence of Uveitis (ITT; all randomized subjects)

<table>
<thead>
<tr>
<th>Study 1</th>
<th>Study 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eyes with recurrence within 12 months, n (%)</td>
<td>24 (28%)</td>
</tr>
<tr>
<td>Difference (95% CI) in recurrence rates</td>
<td>58% (48%, 70%)</td>
</tr>
</tbody>
</table>

16. HOW SUPPLIED/STORAGE AND HANDLING

YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg is supplied in a sterile single-dose preloaded applicator with a 25-gauge needle, packaged in a sealed sterile full pouch inside a sealed Tyvek pouch inside a carton.

NDX: 71879-630-01
Storage: Store at 15° C to 30° C (59° F to 86° F).

17. PATIENT COUNSELING INFORMATION

Steady-state related effects

Advise patients that a cataract may occur after treatment with YUTIQ. If this occurs, advise patients that their vision will decrease, and they will need assistance to operate the car and/or operate their home. Advise patients that they may need to increase intraocular pressure with a new treatment before and/or after cataract surgery.

Driving and Using Machines

Instruct patients that they may experience temporary visual blurring after receiving an intravitreal injection. Advise patients not to drive or use machinery until this has resolved.

Manufactured by:
EyePoint Pharmaceuticals US, Inc.
480 Pleasant Street
Watertown, MA 02472 USA
Patented.